Novelion Therapeutics (NVLN) 10-Q2011 Q1 Quarterly report

Filed: 5 May 11, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: affiliate, aggressive, allergy, analyze, anterior, antibody, arm, ARVO, assigned, attention, Avastin, aware, baseline, bevacizumab, BLA, block, bringing, Butchofsky, calendar, Cameron, CE, Certification, cohort, complementary, contend, copy, CuraScript, deadline, departure, detriment, dry, duly, earthquake, EEC, eluting, equivocal, essentially, evolving, exceed, extensively, favorable, FDA, fewer, flat, furnished, greater, hand, III, inadequate, Index, inflammation, instance, insufficient, intense, Intention, intraocular, introduction, laser, lifecycle, located, maintenance, marketplace, monitor, Nelson, NeoVista, Notice, notion, orphan, outcome, placebo, platform, Preliminary, prescribed, preservation, priority, rapidly, recovery, recruiting, Regeneron, remove, rendered, request, Robert, rolling, SD, sensitive, shifted, showing, side, simplify, slight, Suite, suited, superior, technical, thereunto, Trust, tsunami, undersigned, uneconomical, unexpected, VEGF, volume, week, withdrawal, Yeso

Removed: absorb, accrued, acne, actively, Aczone, Add, adjustment, adrenergic, advance, advanced, advertising, agreed, Allergan, amortization, antagonist, ASU, Atrigel, Auction, award, beneficiary, beta, birth, blocker, bulk, cancellation, cancer, cease, charged, classified, combination, comparative, composed, comprising, concept, contractually, controlling, custom, damage, deductible, degenerative, depreciation, designation, determining, device, disclose, disclosing, discontinued, disposed, disposition, distributing, divestiture, drop, Dutch, dysfunction, enhance, enrolled, enterprise, evaluating, examining, exempt, expense, formal, formulation, freight, government, half, health, impairment, incurred, inherited, initiated, interpretation, invest, judgment, LLC, longer, MEEI, nonmonetary, obsolescence, occur, offer, Opening, orally, Othera, packaging, paragraph, parent, power, prevailing, prodrug, producing, profile, progressive, promoting, pronouncement, prostate, qualifying, quoted, rebate, receiving, reimbursed, represented, resulted, retained, retinal, revaluation, shareholder, subsequent, superseded, surrendered, tender, term, topic, transferor, transferred, transit, translated, unrealized, user, visibility, work

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

NVLN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of QLT Inc. (the “Company”) for the quarterly period ended March 31, 2011, as filed with the Securities and Exchange Commission on the date hereof (the ”Report”), I, Robert L. Butchofsky, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at and for the periods indicated.

Dated: May 5, 2011


	/s/ Robert L. Butchofsky
	Robert L. Butchofsky
	President and Chief Executive Officer (Principal Executive Officer)